Official websites use .mil
Secure .mil websites use HTTPS
Specimens are transported from the submitting units to the laboratory via the US Postal Service, private carrier (FEDEX, DHL, UPS), or hand-delivery. The accessioning department staff examines the package, specimen, and accompanying documentation, and assigns the applicable discrepancy codes. Strict chain of custody is maintained throughout specimen handling and processing. The accessioning department technician prepares an initial testing batch, pours an aliquot of each specimen into individual tubes, and transfers the batch to the screening department to conduct the initial testing analysis using immunoassay instrumentation.
If no drug is detected during the immunoassay testing, the service member’s specimen is reported as negative and the specimen is discarded. If a specimen is presumptively positive, the result is compared against data from the electronic prescription reporting system (ePRS); some drug classes may be reported as negative if there is a valid prescription documented in ePRS within the last 180 days. Specimens that are presumptively positive that are not cleared through ePRS are sequestered for confirmatory analysis using a new aliquot poured from the original specimen bottle. These specimens are tested for drug presence and concentration using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) instrumentation. The drug or metabolites must be present at or above the DOD cutoff, and all quality control and reporting criteria must be satisfied, in order to be reported as positive.
All data generated by the laboratory are subject to multiple reviews by laboratory certifying officials to ensure that all procedures have been followed and that the results are scientifically valid and legally defensible prior to uploading the results to the iFTDTL portal.
The Navy Drug Testing Program is committed to providing scientifically valid and legally defensible drug test results in a timely manner to our customers. Submitting unit commanders require accurate and timely results to assess unit readiness and to take swift action on members when an incident of drug abuse has been determined. The Navy Drug Screening Laboratories employ numerous quality control procedures to ensure the integrity of their results. These procedures include:
Clinical guidance, including recognition, management and clinical isolation guidance are generally covered by CDC: CDC Clinical Overview
Clinical management for Fleet medical personnel can be found in the NMCFHPC Fleet Mpox Medical Guidance
Clinical guidance for MTFs can be found in the DHA Mpox Guidance Update_5Sept2024
Currently, neither mpox testing nor treatment are readily available in a forward deployed operational setting. Units should identify suspected cases, isolate them, and move them for care at an MTF when operationally feasible.
Bureau of Medicine and Surgery 7700 Arlington Blvd. Ste. 5113 Falls Church, VA 22042-5113 This is an official U.S. Navy website This is a Department of Defense (DoD) Internet computer system. General Navy Medical Inquiries (to Bureau of Medicine and Surgery): usn.ncr.bumedfchva.list.bumed---pao@health.mil